Navigation Links
H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
Date:11/26/2012

CAMBRIDGE, Mass., Nov. 26, 2012 /PRNewswire/ -- Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has completed an expansion of its headquarters and laboratory facilities in Cambridge, Massachusetts.  The increase more than doubles the company's original space to approximately 48,000 square feet, including new state-of-the-art laboratories, offices and meeting rooms.  The expansion will support an anticipated staff of 75 employees by the end of 2013, an increase in H3 Biomedicine's employee base of 29 in 2011. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

"While we remain an early-stage, research-focused company, our rapid growth this year marks a significant step toward developing novel oncology drug candidates, and, ultimately, expediting the delivery of new therapies to the patients who need them," said Markus Warmuth, M.D., President and Chief Executive Officer of H3 Biomedicine.  "Our unique corporate culture encourages science-driven work and access to shared resources. We are fortunate to attract top talent while operating in the Cambridge area, where the technical expertise and entrepreneurial spirit are a strong fit for our organization."

In December 2011, H3 Biomedicine opened its headquarters in Cambridge with 24,000 square feet of working space. Eisai Co. Ltd., a research-based human health care (hhc) company, pledged up to $200 million in research funding to H3 Biomedicine and will provide additional support for the company's clinical development programs, including access to many of Eisai's drug development capabilities.

"Eisai's commitment is based on our recognition that H3 Biomedicine possesses strong fundamentals in their science programs and innovative approach toward cancer treatment development," said Haruo Naito, Eisai Co., Ltd. President and CEO. "We are pleased that in this past year alone, the strong growth of their research-based initiatives has brought us closer to the vision of realizing the potential of personalized medicine."

Progress on Major Programs, Collaborations, Contribute to Expansion
H3 Biomedicine's leadership attributes the accelerated growth in large part to the dedication of its scientists, including the bioinformatics team that is driving its cancer genome mining work. These efforts aim to identify and validate recurrent gene mutations that are potential targets for drug therapies—the crucial first step in the company's mission to develop a library of novel oncology candidates for clinical testing. Currently, H3 Biomedicine's lead program is designed to develop drugs that target the gene SF3b1. Several recent publications have implicated mutations in this gene in blood-related malignant conditions, such as myelodysplastic syndromes and chronic lymphocytic leukemia, as well as solid tumors like those associated with skin, breast and pancreatic cancers.  H3 plans to utilize its new facilities to expand operations in pharmacokinetics and preclinical efficacy studies—components crucial to H3's lead program. 

H3 Biomedicine's world-class facilities and technology have also enabled several key collaborations in 2012, including projects with Compendia Bioscience and Horizon Discovery LTD.  "These alliances have tremendous synergy with our own scientific programs," continued Warmuth, "and our expanded facilities will enable us to fulfill the programmatic requirements of additional partnerships in which we participate."

About H3 Biomedicine Inc. 
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.H3biomedicine.com for more information.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Eisai employs approximately 11,000 employees worldwide.


'/>"/>
SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A 300 Million Euro Boost for Biomedicine in Berlin
2. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
3. Why Texas is #1 in Business: Local BioTech Company Expands
4. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
5. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
6. Elsevier Expands Access to Digital Offerings Through Collaboration with Follett
7. BioStorage Technologies Expands its Service Offering to Include Advanced Bioprocessing Solutions
8. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
9. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
10. Medtech Expands Nursing Education Opportunities In Florida
11. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... just published their findings on what they believe could be a new and ... of the new research. Click here to read it now. , ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):